140 related articles for article (PubMed ID: 34923718)
21. Homologous Recombination Deficiencies and Hereditary Tumors.
Yamamoto H; Hirasawa A
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008774
[TBL] [Abstract][Full Text] [Related]
22. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
Hu C; Nagaraj AB; Shimelis H; Montalban G; Lee KY; Huang H; Lumby CA; Na J; Susswein LR; Roberts ME; Marshall ML; Hiraki S; LaDuca H; Chao E; Yussuf A; Pesaran T; Neuhausen SL; Haiman CA; Kraft P; Lindstrom S; Palmer JR; Teras LR; Vachon CM; Yao S; Ong I; Nathanson KL; Weitzel JN; Boddicker N; Gnanaolivu R; Polley EC; Mer G; Cui G; Karam R; Richardson ME; Domchek SM; Yadav S; Hruska KS; Dolinsky J; Weroha SJ; Hart SN; Simard J; Masson JY; Pang YP; Couch FJ
Cancer Res; 2023 Aug; 83(15):2557-2571. PubMed ID: 37253112
[TBL] [Abstract][Full Text] [Related]
23. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
[TBL] [Abstract][Full Text] [Related]
24. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
25. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
[TBL] [Abstract][Full Text] [Related]
26. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
27. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Meindl A; Hellebrand H; Wiek C; Erven V; Wappenschmidt B; Niederacher D; Freund M; Lichtner P; Hartmann L; Schaal H; Ramser J; Honisch E; Kubisch C; Wichmann HE; Kast K; Deissler H; Engel C; Müller-Myhsok B; Neveling K; Kiechle M; Mathew CG; Schindler D; Schmutzler RK; Hanenberg H
Nat Genet; 2010 May; 42(5):410-4. PubMed ID: 20400964
[TBL] [Abstract][Full Text] [Related]
28. Functional characterization and identification of mouse Rad51d splice variants.
Gruver AM; Yard BD; McInnes C; Rajesh C; Pittman DL
BMC Mol Biol; 2009 Mar; 10():27. PubMed ID: 19327148
[TBL] [Abstract][Full Text] [Related]
29. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
30. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
31. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
[TBL] [Abstract][Full Text] [Related]
33. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
[TBL] [Abstract][Full Text] [Related]
34. Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM
Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143
[TBL] [Abstract][Full Text] [Related]
35. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
36. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families.
Romero A; Pérez-Segura P; Tosar A; García-Saenz JA; Díaz-Rubio E; Caldés T; de la Hoya M
Breast Cancer Res Treat; 2011 Oct; 129(3):939-46. PubMed ID: 21537932
[TBL] [Abstract][Full Text] [Related]
37. Germline mutations in RAD51, RAD51AP1, RAD51B, RAD51C,RAD51D, RAD52 and RAD54L do not contribute to familial chronic lymphocytic leukemia.
Sellick G; Fielding S; Qureshi M; Catovsky D; ; Houlston R
Leuk Lymphoma; 2008 Jan; 49(1):130-3. PubMed ID: 18203022
[TBL] [Abstract][Full Text] [Related]
38. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
39. RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.
Le Calvez-Kelm F; Oliver J; Damiola F; Forey N; Robinot N; Durand G; Voegele C; Vallée MP; Byrnes G; Registry BC; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV; Lesueur F
PLoS One; 2012; 7(12):e52374. PubMed ID: 23300655
[TBL] [Abstract][Full Text] [Related]
40. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
